Oulhen M[Author] - Search Results

Year	Number of Results
2012	1
2013	1
2015	1
2016	2
2017	4
2018	1
2019	4
2020	3
2021	3
2022	1
2024	1

1

Young R, Pailler E, Billiot F, Drusch F, Barthelemy A, Oulhen M, Besse B, Soria JC, Farace F, Vielh P. Young R, et al. Among authors: oulhen m. Acta Cytol. 2012;56(6):655-60. doi: 10.1159/000345182. Epub 2012 Nov 24. Acta Cytol. 2012. PMID: 23207444 Review.

2

CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs).

Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F. Tayoun T, et al. Among authors: oulhen m. Cells. 2019 Sep 25;8(10):1145. doi: 10.3390/cells8101145. Cells. 2019. PMID: 31557946 Free PMC article. Review.

3

Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.

Tayoun T, Oulhen M, Aberlenc A, Farace F, Pawlikowska P. Tayoun T, et al. Among authors: oulhen m. Cells. 2021 Feb 5;10(2):337. doi: 10.3390/cells10020337. Cells. 2021. PMID: 33562741 Free PMC article. Review.

4

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.

Ross K, Pailler E, Faugeroux V, Taylor M, Oulhen M, Auger N, Planchard D, Soria JC, Lindsay CR, Besse B, Vielh P, Farace F. Ross K, et al. Among authors: oulhen m. Expert Rev Mol Diagn. 2015;15(12):1605-29. doi: 10.1586/14737159.2015.1111139. Epub 2015 Nov 13. Expert Rev Mol Diagn. 2015. PMID: 26564313 Review.

5

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.

Pawlikowska P, Faugeroux V, Oulhen M, Aberlenc A, Tayoun T, Pailler E, Farace F. Pawlikowska P, et al. Among authors: oulhen m. J Thorac Dis. 2019 Jan;11(Suppl 1):S45-S56. doi: 10.21037/jtd.2018.12.80. J Thorac Dis. 2019. PMID: 30775027 Free PMC article. Review.

6

Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer.

Catelain C, Pailler E, Oulhen M, Faugeroux V, Pommier AL, Farace F. Catelain C, et al. Among authors: oulhen m. Adv Exp Med Biol. 2017;994:169-179. doi: 10.1007/978-3-319-55947-6_9. Adv Exp Med Biol. 2017. PMID: 28560674 Review.

7

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.

Mezquita L, Oulhen M, Aberlenc A, Deloger M, Aldea M, Honore A, Lecluse Y, Howarth K, Friboulet L, Besse B, Planchard D, Farace F. Mezquita L, et al. Among authors: oulhen m. Br J Cancer. 2024 Mar;130(4):682-693. doi: 10.1038/s41416-023-02535-0. Epub 2024 Jan 4. Br J Cancer. 2024. PMID: 38177660 Free PMC article.

8

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?

Pailler E, Faugeroux V, Oulhen M, Catelain C, Farace F. Pailler E, et al. Among authors: oulhen m. Transl Lung Cancer Res. 2017 Aug;6(4):444-453. doi: 10.21037/tlcr.2017.07.01. Transl Lung Cancer Res. 2017. PMID: 28904888 Free PMC article. Review.

9

Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants.

Tayoun T, Faugeroux V, Oulhen M, Déas O, Michels J, Brulle-Soumare L, Cairo S, Scoazec JY, Marty V, Aberlenc A, Planchard D, Remon J, Ponce S, Besse B, Kannouche PL, Judde JG, Pawlikowska P, Farace F. Tayoun T, et al. Among authors: oulhen m. JCI Insight. 2022 Jun 8;7(11):e155804. doi: 10.1172/jci.insight.155804. JCI Insight. 2022. PMID: 35511434 Free PMC article.

10

Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID.

Neves RPL, Ammerlaan W, Andree KC, Bender S, Cayrefourcq L, Driemel C, Koch C, Luetke-Eversloh MV, Oulhen M, Rossi E, Alix-Panabières C, Betsou F, Farace F, Riethdorf S, Schlange T, Wikman H, Zamarchi R, Pantel K, Terstappen LWMM, Stoecklein NH; CANCER-ID Consortium. Neves RPL, et al. Among authors: oulhen m. Clin Chem. 2021 Mar 31;67(4):631-641. doi: 10.1093/clinchem/hvaa322. Clin Chem. 2021. PMID: 33491069

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

21 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year